By Connor Hart
Jacobs Solutions disclosed post-closing adjustments stemming from a transaction it completed with Amentum last year. The Dallas company received $70 million and the right to receive nearly 7.3 million shares of Amentum's common stock. Jacobs used the money to repay a portion of debt and plans to distribute Amentum's stock to its shareholders. Shares up 6.9%, to $122.80, in after-hours trading.
Argenx received approval from the Food and Drug Administration for a new delivery method of its treatment for certain patients with a rare autoimmune disease. The approval of the treatment, Vyvgart Hytrulo, in a prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to the treatment in a vial, the immunology company said. The prefilled syringe is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver or healthcare professional. American depositary receipts rise 6.2%, to $580, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 10, 2025 19:29 ET (23:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。